Treatment of diabetes and heart failure: joint forces
Abstract
This editorial refers to ‘Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial’†, by D. Fitchett et al. on page 1526. People with type 2 diabetes mellitus (T2DM) are at increased risk of future cardiovascular disease, and chronic heart failure (CHF) is an important complication and cause of mortality. It has been estimated that the proportion of CHF patients with known T2DM is 20–35%.1 A Swedish registry report confirms that 25% of patients diagnosed with CHF in all day practice have previously known T2DM, a majority of ischaemic origin.2 The true proportion is probably considerably higher since undiagnosed T2DM is common, not least in populations with cardiovascular diseases.3 Further, in the population, a diagnosis of CHF is twice as common among patients with than among those without T2DM.4 The combination of T2DM and HF is expected to rise in the future, partly due to the increase in prevalence and longevity of patients with T2DM, but also due to improved survival after myocardial infarction and a more systematic screening for the combination.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.